Goldstein E J, Conrads G, Citron D M, Merriam C V, Warren Y, Tyrrell K
R. M. Alden Research Laboratory Santa Monica-UCLA Medical Center, Santa Monica, California 90404, USA.
Antimicrob Agents Chemother. 2001 Aug;45(8):2363-7. doi: 10.1128/AAC.45.8.2363-2367.2001.
The comparative in vitro activities of ABT-773 against 207 aerobic and 162 anaerobic antral sinus puncture isolates showed that erythromycin-resistant pneumococcal strains were susceptible to ABT-773 (< or =0.125 microg/ml); the MIC at which 90% of the isolates tested were inhibited for Haemophilus influenzae and other Haemophilus spp. was 4 microg/ml; and all Moraxella spp. and beta-lactamase-producing Prevotella species strains were inhibited by < or =0.125 microg/ml. Among the anaerobes tested, only fusobacteria (45%) required > or =4 microg of ABT-773/ml for inhibition. ABT-773 may offer a therapeutic alternative for sinus infections.
ABT - 773对207株需氧菌和162株厌氧性鼻窦穿刺分离菌的体外比较活性研究表明，对红霉素耐药的肺炎球菌菌株对ABT - 773敏感（≤0.125微克/毫升）；90%受试流感嗜血杆菌及其他嗜血杆菌属菌株被抑制时的最低抑菌浓度（MIC）为4微克/毫升；所有莫拉克斯氏菌属及产β - 内酰胺酶的普雷沃氏菌属菌株均被≤0.125微克/毫升的ABT - 773所抑制。在受试厌氧菌中，只有梭杆菌（45%）被抑制时所需的ABT - 773浓度≥4微克/毫升。ABT - 773可能为鼻窦感染提供一种治疗选择。
